News
Human Cell Programming Firm bit.bio Secures $25M Series D Amid Surging Demand
FundingNovember 6, 2026, 3:37 pm
Human cell programming firm bit.bio secured $25 million in Series D funding. The investment expands its human cell model portfolio. It also increases access for pharmaceutical companies, biotech businesses, and research organizations. This funding arrives amid surging demand for human-relevant experimental models. Advances in AI accelerate drug candidate identification. The shift away from traditional animal models also fuels this need. bit.bio’s proprietary opti-ox™ platform produces defined human cell types consistently and at scale. This technology addresses issues like donor variability and limited supply. The company plans global commercial growth. It supports faster, more accurate drug discovery and toxicology.
Cambridge, UK – Human cell programming leader bit.bio has closed a significant $25 million Series D funding round. This new capital infusion propels the company's ambitious expansion plans. It targets an enlarged portfolio of human cell models. It also aims to broaden access for key industry players. Pharmaceutical firms, biotechnology businesses, and research organizations stand to benefit.
The investment follows bit.bio's successful Series C round earlier this year. It signals continued investor confidence. Existing backer M&G Investments participated. Dr. Jonathan Milner, a seasoned life sciences entrepreneur, also contributed. Milner is the founder and former CEO of Abcam.
Drug discovery methods are evolving rapidly. Researchers demand more reliable experimental models. These models must predict treatment behavior in humans with greater accuracy. Traditional animal models present inherent limitations. Biological differences between species often hinder direct translation. This drives a powerful industry shift. Human cell-based alternatives now gain critical traction. They promise more relevant testing. They also reduce reliance on animal experiments.
Simultaneously, artificial intelligence revolutionizes drug development. AI accelerates the identification and design of potential drug candidates. This creates an urgent need. Consistent and reproducible human cell models are essential. They evaluate safety and effectiveness. bit.bio directly addresses these critical industry challenges.
The company leverages its proprietary opti-ox™ platform. This innovative technology enables precise production. It generates defined human cell types. It does so consistently and at immense scale. The platform overcomes common limitations. Donor variability often plagues traditional cell models. Restricted cell supply also poses a significant hurdle. bit.bio provides researchers with reliable models for experimental use.
The ioCells portfolio represents bit.bio's product offering. It currently includes over 50 human cell types. These include critical models for various systems. Heart, liver, and central nervous system models are part of the catalog. These versatile cells support diverse applications. Disease research benefits greatly. Functional genomics, drug discovery, and toxicology studies also rely on them.
Demand for these advanced human cell models has surged. bit.bio reports record-breaking growth. Paid vial volumes increased by an impressive 76% year-to-date in 2026. Order volumes climbed 34%. The active customer base grew by 40%. Academic customer growth was particularly strong, reaching 63%. This robust demand underscores a fundamental shift in research.
The industry stands at a pivotal inflection point. AI redefines the pace of new medicine discovery. The move away from animal testing accelerates. Both trends converge on one critical need. Vast quantities of consistent human cell models are indispensable. bit.bio positions itself as a key supplier for this demand.
With established manufacturing infrastructure, the company focuses on expansion. New funding will introduce more human cell types. It will also broaden access to its existing products. bit.bio aims to solidify its market position. It strives to be the leading supplier of standardized biological models. These models are crucial for drug discovery and development.
Investors express strong confidence in bit.bio's trajectory. M&G Investments sees substantial potential. They back ambitious businesses reaching new commercial growth phases. bit.bio embodies this opportunity. It possesses proven technology. It boasts established manufacturing capabilities. It experiences growing customer demand. The company is poised for global scaling. It can establish human cell models as an increasingly vital component of life sciences research.
Dr. Jonathan Milner’s involvement brings invaluable experience. His career centered on building successful life sciences tools businesses. He understands the path from scientific idea to industry-shaping company. Milner highlights the fundamental need for consistent human cells. He envisions bit.bio becoming a defining force. The company could build the essential cell platform for researchers worldwide.
bit.bio's strategic focus is clear. It aims to translate surging demand into sustained commercial growth. It supports the development and testing of new medicines. The company intends to make standardized human cell models widely available. This accessibility will advance research methods. It will also improve the predictive value of preclinical testing. The future of medicine increasingly depends on these advanced cellular systems. bit.bio actively shapes that future.
Cambridge, UK – Human cell programming leader bit.bio has closed a significant $25 million Series D funding round. This new capital infusion propels the company's ambitious expansion plans. It targets an enlarged portfolio of human cell models. It also aims to broaden access for key industry players. Pharmaceutical firms, biotechnology businesses, and research organizations stand to benefit.
The investment follows bit.bio's successful Series C round earlier this year. It signals continued investor confidence. Existing backer M&G Investments participated. Dr. Jonathan Milner, a seasoned life sciences entrepreneur, also contributed. Milner is the founder and former CEO of Abcam.
Drug discovery methods are evolving rapidly. Researchers demand more reliable experimental models. These models must predict treatment behavior in humans with greater accuracy. Traditional animal models present inherent limitations. Biological differences between species often hinder direct translation. This drives a powerful industry shift. Human cell-based alternatives now gain critical traction. They promise more relevant testing. They also reduce reliance on animal experiments.
Simultaneously, artificial intelligence revolutionizes drug development. AI accelerates the identification and design of potential drug candidates. This creates an urgent need. Consistent and reproducible human cell models are essential. They evaluate safety and effectiveness. bit.bio directly addresses these critical industry challenges.
The company leverages its proprietary opti-ox™ platform. This innovative technology enables precise production. It generates defined human cell types. It does so consistently and at immense scale. The platform overcomes common limitations. Donor variability often plagues traditional cell models. Restricted cell supply also poses a significant hurdle. bit.bio provides researchers with reliable models for experimental use.
The ioCells portfolio represents bit.bio's product offering. It currently includes over 50 human cell types. These include critical models for various systems. Heart, liver, and central nervous system models are part of the catalog. These versatile cells support diverse applications. Disease research benefits greatly. Functional genomics, drug discovery, and toxicology studies also rely on them.
Demand for these advanced human cell models has surged. bit.bio reports record-breaking growth. Paid vial volumes increased by an impressive 76% year-to-date in 2026. Order volumes climbed 34%. The active customer base grew by 40%. Academic customer growth was particularly strong, reaching 63%. This robust demand underscores a fundamental shift in research.
The industry stands at a pivotal inflection point. AI redefines the pace of new medicine discovery. The move away from animal testing accelerates. Both trends converge on one critical need. Vast quantities of consistent human cell models are indispensable. bit.bio positions itself as a key supplier for this demand.
With established manufacturing infrastructure, the company focuses on expansion. New funding will introduce more human cell types. It will also broaden access to its existing products. bit.bio aims to solidify its market position. It strives to be the leading supplier of standardized biological models. These models are crucial for drug discovery and development.
Investors express strong confidence in bit.bio's trajectory. M&G Investments sees substantial potential. They back ambitious businesses reaching new commercial growth phases. bit.bio embodies this opportunity. It possesses proven technology. It boasts established manufacturing capabilities. It experiences growing customer demand. The company is poised for global scaling. It can establish human cell models as an increasingly vital component of life sciences research.
Dr. Jonathan Milner’s involvement brings invaluable experience. His career centered on building successful life sciences tools businesses. He understands the path from scientific idea to industry-shaping company. Milner highlights the fundamental need for consistent human cells. He envisions bit.bio becoming a defining force. The company could build the essential cell platform for researchers worldwide.
bit.bio's strategic focus is clear. It aims to translate surging demand into sustained commercial growth. It supports the development and testing of new medicines. The company intends to make standardized human cell models widely available. This accessibility will advance research methods. It will also improve the predictive value of preclinical testing. The future of medicine increasingly depends on these advanced cellular systems. bit.bio actively shapes that future.